SEC Contract Filing

Filing Date: 2017-05-09

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d380147dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE <FONT STYLE="white-space:nowrap">24B-2</FONT> PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT #2 TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Amendment #2 to LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (&#147;<B>Amendment</B>&#148;), is entered into between Syndax Pharmaceuticals,
Inc., a Delaware corporation having a place of business at 400 Totten Pond Road, Suite 110, Waltham, MA 02451 USA (&#147;<B>Syndax</B>&#148;) and Kyowa Hakko Kirin Co., Ltd., a Japanese corporation having a place of business at <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-9-2,</FONT></FONT> Otemachi, <FONT STYLE="white-space:nowrap">Chiyoda-ku,</FONT> Tokyo <FONT STYLE="white-space:nowrap">100-0004,</FONT> Japan (&#147;<B>KHK</B>&#148;), effective as of
January&nbsp;16, 2017 (the &#147;Amendment Effective Date&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to that the LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by
and between Syndax and KHK entered into as of December&nbsp;19, 2014 (&#147;<B>Agreement</B>&#148;), as previously amended. As of the Amendment Effective Date, the Agreement is hereby further amended as set forth in this Amendment. Capitalized terms
used but not defined herein shall have the meanings assigned to such terms in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The parties agree that the following new sentences are
hereby added at the end of Section&nbsp;4.4: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Syndax shall use best efforts to ensure that a laboratory *** at the Medical Oncology
Branch, Center for Cancer Research, National Cancer Institute (&#147;NCI&#148;), which has performed or is performing analyses of blood samples from one or more Clinical Trials on Entinostat for Syndax under the Cooperative Research and Development
Agreement #836 &#147;Preclinical and Clinical Development of <FONT STYLE="white-space:nowrap">MS-275</FONT> <FONT STYLE="white-space:nowrap">(NSC-706995),</FONT> a Histone Deacetylase Inhibitor, as an Anti-Cancer Agent&#148; (CRADA), will, pursuant
to KHK&#146;s request, perform analyses of blood samples from one or more Territory Trials in Japan on Entinostat being conducted by KHK (or its licensees) and provide to KHK the data developed or generated therefrom. Unless otherwise agreed upon
between Syndax and KHK, the cost of such analyses of blood samples to be paid to NCI shall be the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Total cost will be USD *** for *** samples. If the number of sample is more than *** samples, additional costs will be USD *** per sample. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Syndax will pay to NCI USD *** as an initial payment upon the execution of the amendment #12 of the CRADA with NCI. Syndax will pay to NCI the remaining cost, USD *** plus the additional costs for more than *** samples
(if necessary), when NCI has completed the measurement. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">The total cost shall not exceed USD *** without the express written consent of Syndax and KHK. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further,
Syndax shall use best efforts to ensure that NCI will keep the documents of the results for and on behalf of KHK at least for *** after the end of such blood sample analyses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the foregoing, the cost of such work for analyses of blood samples from the Territory Trials and document retention will be borne by KHK using the
following procedure: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment for such support will be *** in connection with performing such analyses and document retention, due on a ***. Syndax will